Clinical Trial Update: A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating two dose levels of taliglucerase alfa in pediatric Gaucher disease subjects; completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• Taliglucerase alfa (taliglucerase alfa)

Snippet

Sponsor: Pfizer | Conditions: Gaucher Disease | Phase 4 | Status: COMPLETED | Results posted: 2014-11-11